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SUMMARY
OBJECTIVE—To determine hospitalization expenditures for tuberculosis (TB) disease among 
privately insured patients in the United States.
METHODS—We extracted TB hospital admissions data from the 2010–2014 
MarketScan®commercial database using International Classification of Diseases version 9 codes 
for TB (011.0–018.96) as the principal diagnosis. We estimated adjusted average expenditures (in 
2014 USD) using regression analyses controlling for patient and claim characteristics. We also 
estimated the total expenditure paid by enrollee and insurance, and extrapolated it to the entire US 
employer-based privately insured population.
RESULTS—We found 892 TB hospitalizations representing 825 unique enrollees over the 5-year 
period. The average hospitalization expenditure per person (including multiple hospitalizations) 
was US$33 085 (95%CI US$31 606– US$34 565). Expenditures for central nervous system TB 
(US$73 065, 95%CI US$59 572–US$86 558), bone and joint TB (US$56 842, 95%CI US$39 
301–US$74 383), and miliary/disseminated TB (US$55 487, 95%CI US$46 101–US$64 873) 
were significantly higher than those for pulmonary TB (US$28 058, 95%CI US$26 632–US$29 
484). The overall total expenditure for hospitalizations for TB disease over the period (2010–2014) 
was US$38.4 million; it was US$154 million when extrapolated to the entire employer-based 
privately insured population in the United States.
CONCLUSIONS—Hospitalization expenditures for some forms of extra-pulmonary TB were 
substantially higher than for pulmonary TB.
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In the united states, active TB disease is typically successfully treated with 6 months of a 
combination of anti-tuberculosis drugs, often administered on an out-patient basis using 
directly observed therapy (DOT).1,2 Although out-patient-based anti-tuberculosis treatment 
represents a shift from the sanatoria-based approach common before the 1960s,3,4 one recent 
study of a cohort of TB patients reported that almost half (49%) of patients were 
hospitalized during TB diagnosis or treatment in the United States.3,5
Most (77%) TB prevention and control efforts (mainly diagnostic and treatment services) are 
provided by the public sector through local health departments; however, the introduction of 
the Affordable Care Act will likely increase the provision of TB health care services in the 
private sector.6 As most of the direct costs of TB treatment come from hospitalization,3,5 
information on TB hospitalization can be useful for estimating resource use in TB 
prevention and control activities. Moreover, expenditure estimates for TB hospitalization 
among individuals with private insurance are important inputs when modeling the economic 
outcomes and burden on various payers of TB testing and prevention programs.
Although several studies have reported on TB hospitalization resource use, most of these are 
outdated (over two decades old5,7,8), presented data on hospital charges (not cost), described 
individual hospitalization episodes (excluded analysis of multiple TB hospitalizations per 
person), or reported estimates that excluded physician fees/charges.1,4,9 In the present study, 
we estimated the average and total expenditures (paid by enrollee and insurance) for TB 
hospitalizations for persons with private insurance in the US by analyzing 2010–2014 in-
patient claims data—a private sector perspective.
MATERIALS AND METHODS
For this study, in-patient claims data on private insurance claims for reimbursement from the 
Truven Health MarketScan® Commercial Claims Database (Truven Health Analytics, Ann 
Arbor, MI, USA) for 2010–2014 were analyzed. The 2010–2014 data contained claims 
information on at least 43 million people each year, which included employees, their 
spouses, and dependents (MarketScan). Based on the reported overall total employer-based 
privately insured population in the United States for 2010–2014, the annual enrollments 
provided in the database suggest that ≥25% of this population were represented in the 
database.10–12
Using the International Classification of Diseases version 9 (ICD-9) codes for TB (011.0–
018.96), we identified and extracted in-patient admission claims information for all patients 
from the 2010–2014 in-patient records. Each record has a ‘principal diagnosis’ code (i.e., the 
main reason for in-patient stay13) and up to 14 secondary diagnosis codes. However, because 
our objective was to estimate expenditures that were likely attributable to hospitalization for 
TB disease, we restricted the extracted data to in-patient records having a principal diagnosis 
of TB disease, i.e., one of the TB ICD-9 codes specified above.
The MarketScan data contain fully adjudicated and paid insurance claims (total payments).14 
Each hospital admission record included information on total payments by both enrollee and 
private insurance plan.13 Total payments also included both hospital and physician 
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payments.13 Preliminary analyses indicated that some patients had more than one admission 
during the period covered (i.e., 2010–2014); because we wanted to estimate hospitalization 
expenditures per patient, we aggregated the associated payments and the duration of 
hospitalization (i.e., length of stay) for each patient.
Given the potential for the magnitude of the payments to differ substantially depending on 
the site of TB disease (i.e., extra-pulmonary TB [EPTB]), we controlled for (and estimated) 
the average expenditures for the different TB disease sites identified from the ICD-9 codes. 
Specifically, we used the following categories: pulmonary TB (PTB), other respiratory, 
central nervous system (CNS), intestinal, bone and joint, genitourinary/not elsewhere 
classified and miliary/disseminated. We totaled the expenditures for all the TB disease in-
patient records that we identified and extrapolated these to estimate the total expenditures of 
TB hospitalizations for the entire US population with employer-based health insurance 
during the period of the analysis (2010–2014).
We used regression analyses to estimate the adjusted averages for all TB diseases, as well as 
for each EPTB category. As expenditures for 2010–2013 were adjusted to 2014 USD using 
the medical care component of the consumer price index,15 all the reported expenditure 
estimates were in 2014 USD.
Regression analyses
Because all the expenditure data were positive, highly skewed and right-tailed, we used the 
generalized linear model (GLM) technique with log link and gamma distribution.16,17 As in 
previously published studies,1,17–19 we controlled for selected patient and claim 
characteristics based on the categories in the database13 that included length of stay (days), 
age group (<15, 15–44 and ≥45 years), sex (male/female), number of admissions, admission 
type (surgical/medical), discharge status (dead/alive), drug benefit (whether or not enrollee’s 
insurance plan included prescription drug coverage), region of the United States (South/
Northeast/North/Central/West/unknown) and type of health plan (preferred provider 
organization [PPO]/comprehensive/exclusive provider organization/health maintenance 
organization/point of service [POS]/consumer driven health plan/high deductible health 
plan).17–19
To reduce the potential problem of high multi-collinearity, which can affect the magnitude 
and therefore the interpretation of the estimated coefficients of the control variables,20 we 
checked the variance inflation factor (VIF < 10) and condition number (<15) based on 
Belsley et al.’s criteria.21 Given the log-link specification, we transformed the coefficients 
from the regression analyses to interpret the results. For continuous control variables, we 
calculated the coefficient (β)*100 and interpreted them as the relative change (in percentage) 
per small change in the control variable. For categorical control variables, we calculated (eβ 
− 1)*100 and interpreted them as the relative difference (in percentage) in the estimated 
expenditures when compared to the referent category.22
The in-patient data were extracted using Data-Probe®, online version 5.2.11 (Truven Health 
Analytics Inc, Ann Arbor, MI, USA). The GLM estimation with log link and gamma 
distribution as well as the regression validation and diagnostics were executed in STATA, 
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version 14.0 (StataCorp LP, College Station, TX, USA). Microsoft Excel, version 2013 
(Microsoft Corporation, Redmond, WA, USA) was used for presentation of summary 
results.
As all the data used in this study were from the MarketScan database, which contains 
retrospective data on de-identified enrollees (MarketScan), institutional review board 
approval was not required.
RESULTS
Table 1 shows the frequency of TB hospitalization by patient and claim characteristics. 
There were 892 TB hospitalizations representing 825 unique enrollees. Approximately 93% 
(n=769) of the patients had one TB hospitalization. Of the remaining 7% (n =56), 48 had 
two unique admissions, six had three admissions each, one had four admissions and another 
one had five unique admissions. For those with multiple admissions, we found that the 
largest gap in admissions (the difference between two successive admissions) for any patient 
was 481 days.
The average length of stay was 10 days (standard deviation 12, median 8, range 1–121). A 
slightly higher proportion of TB in-patients were aged ≥ 45 years compared with those aged 
15–44 years (47% vs. 46%), while only 7% were pediatric in-patients (age <15 years). The 
majority (71%) of the admissions were coded as medical (vs. surgical). Based on discharge 
data, 2% of the patients (n =16) died and the remainder were discharged, transferred to 
another facility or left against medical advice (Table 1). Patients were slightly more likely to 
be male than female (56% vs. 44%). The region with the highest proportion of TB patients 
was the South (39%), followed by the West (23%). The North Central region had the lowest 
number of TB patients (15%). Approximately 2% of the patient location data were unknown 
or missing. A large majority of the TB admissions were for PTB (≈72%), while the other six 
TB disease site categories (EPTB diseases: other respiratory, CNS, intestinal, bone and joint, 
genitourinary/not elsewhere classified and miliary/disseminated) were fairly evenly 
distributed, ranging from 4% to 6%. We found 17–22% of total TB patients in each year we 
analyzed. The majority (75%) of the patients had drug benefits. Finally, the PPO was the 
dominant type of health plan, accounting for two thirds of the health plan types (Table 1).
Regression analyses
Table 2 shows the final regression results that were used to estimate the adjusted average 
expenditures for TB hospitalization for all TB disease sites taken together. Although, as 
expected, there were significant pair-wise correlations between some of the control 
variables, they were not high enough to cause multicollinearity problems, based on the 
criteria we used; the two highest correlation coefficients were: >1 admission vs. length of 
stay (ρ =0.45, P < 0.01) and >1 admission vs. CNS site of disease (0.20, P < 0.01). Our 
check for multicollinearity problems indicated that the VIF (mean 1.43, highest 4.57) and 
condition number (4.2) were all below the limits proposed by Belsley et al.21
The results indicate that an increase in the length of stay by 1 day increased average 
expenditure by 4% (P < 0.01). The expenditures for patients aged ≥ 45 years were 22% 
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higher than for those aged <15 years (P < 0.01). The expenditures for those with more than 
one in-patient admission were 36% higher than for those with one admission (P < 0.01). The 
expenditures for admission type coded as medical were 40% lower than those coded as 
surgical (P < 0.01). When compared to the expenditures from patients in the South, 
expenditures on patients from the Northeast and West were respectively 26% (P < 0.01) and 
91% (P < 0.01) higher. The expenditures for CNS TB, bone and joint TB, and miliary/
disseminated TB were higher than those for PTB, by respectively 106% (P < 0.01), 59% (P 
< 0.01) and 26% (P < 0.05). The expenditure for CNS TB was thus more than double that 
for PTB. The expenditures from the POS health plan type were 23% higher than those from 
the PPO plan (P < 0.05).
A summary of the estimated adjusted and unadjusted average expenditures for all hospital 
admissions for TB disease (and disease site categories) are presented in Table 3. We 
estimated that the average hospitalization expenditure for all TB admissions was US$33 085 
(95% confidence interval [CI] US$31 606–US$34 565). Hospitalization expenditures for TB 
disease site categorized as CNS (US$73 065, 95%CI US$59 572–US$86 558), bone and 
joint (US$56 842, 95%CI US$39 301–US$74 383] and miliary/disseminated (US$55 487, 
95%CI US$46 101–US$64 873) TB were significantly higher (P < 0.05) than for PTB (US
$28 058, 95%CI US$26 632–US$29 484). The total expenditures for TB hospitalization 
were US$38.4 million over the 5-year period (2010–2014) of this analysis, and US$154 
million when extrapolated to the entire employer-based private insurance population in the 
United States.
DISCUSSION
We analyzed 2010–2014 in-patient private insurance claims data to estimate expenditures for 
persons with private insurance associated with TB hospitalization. Based on our findings, 
there were 892 admission records representing 825 unique enrollees (≈7% had more than 
one TB hospitalization). The annual number of hospitalized TB patients we identified 
represents less than 2% of the cases reported in US surveillance data.23 From hospital 
discharge data, we found that 2% (n =16) of hospitalized patients were known to have died. 
The estimated adjusted average hospitalization expenditures per hospitalized TB patient with 
private insurance were US$33 085 (in 2014 dollars). While the majority of TB 
hospitalizations were for PTB (≈72%), our analyses indicated that the estimated adjusted 
average hospitalization expenditures for some EPTB diseases (CNS, US$73 065; bone and 
joint, US$56 842; and disseminated, US$55 487) were significantly higher than for PTB. We 
estimated total expenditures for TB hospitalizations over the period (2010–2014) at US$38.4 
million. Extrapolated to the entire US employer-based privately insured population, the total 
expenditures for TB hospitalizations over the period were estimated at US$154 million.
Our estimate of the average medical expenditures for TB disease hospitalization was 
substantially higher than the estimate (updated to 2014 dollars) reported by Holmquist et al.4 
(US$26 000) from the Healthcare Utilization Project, which includes public insurance 
payers. This was because Holmquist et al.4 reported hospitalization costs, which do not 
include physician fees,8,9 while the total in-patient payments provided in the MarketScan 
database included physician and hospital payments.13 When we focused on hospital-only 
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payments, our estimate was similar, at US$27 000 (rounded to the nearest thousands). Our 
expenditures estimate was also similar to the hospitalization cost estimate of US$31 000 
(updated to 2014 dollars) reported by Marks et al.24 The 2% hospitalization fatality rate in 
MarketScan data was within the range reported by previous studies (2–12%),1,25–27 although 
it was at the low end of the range.
Limitations
One major limitation of our study was that we could not differentiate multidrug-resistant 
(MDR) or extensively drug-resistant (XDR) TB from drug-susceptible TB. This was because 
we relied exclusively on ICD-9 codes to identify TB cases. Unfortunately, there are no codes 
specific to MDR-/XDR-TB. Furthermore, we did not have complete medical history data. 
However, MDR-/XDR-TB patients make up only about 1% of annual TB cases,28 and their 
hospitalization costs, for those patients who survived, would have been at the high end of 
our estimates.24 Our estimate does not include productivity or intangible costs (such as pain 
and suffering) incurred by the patients, nor does it include TB-related ancillary costs from 
out-patient visits or prescription drugs. Although we accounted for multiple admissions in 
our analyses, we could not determine whether subsequent visits were new cases (recurrent 
TB) or relapse cases.
As described above, we focused on the principal diagnosis for identifying TB disease as the 
main reason for hospital admission. However, the use of ICD-9 codes to identify TB disease 
has its limitations.29,30 Our method of identification might have missed TB cases that were 
mistakenly recorded as a secondary diagnosis. As a result, we might have under/
overestimated the number of TB cases that we identified in this study, although the degree 
and direction of the biases (in the number of cases and the associated cost estimates) is 
difficult to assess based on the available data. Additional data analyses, such as laboratory 
results and chart reviews, might help to improve the sensitivity and specificity of the 
identification process used in this study.31
The MarketScan database has some limitations. It contains information on selected 
employers/health plans that are largely based on the company’s inclination to participate. It 
is therefore a convenience sample that does not include medium and small firms,32 and 
might not be generalizable to the entire employer-based privately insured population in the 
United States. The rough estimate that we provided by extrapolating to the entire US 
employer-based privately insured population in 2010–2014 should therefore be interpreted 
with caution. For one or a combination of reasons, including clinician, data unavailability, or 
data entry errors, there may be some inaccurate/missing information.33,34
Strengths
Despite the limitations discussed above, this study has several strengths. First, the database 
is one of the largest private insurance databases in the United States. Reported data on the 
employer-based privately insured population in the United States suggest that the 
MarketScan database contained data on ≥25% of the employer-based privately insured 
population each year over the 5-year period covered in this study (2010–2014).10–12 Second, 
the medical expenditures information provided in the database are total payments (not 
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charges), which included physician payments. Our estimates therefore represent actual full 
dollar amounts paid by the insurance companies and enrollees for the medical services 
provided for these in-patients in 2010–2014.32,35 Furthermore, our study adds to the 
literature by providing previously unavailable estimates for the less common EPTB diseases, 
such as CNS, bone and joint, and miliary/disseminated TB. We did not find any study that 
explicitly estimated hospitalization costs/expenditures for EPTB diseases. Finally, our study 
provides relevant private insurance perspective information on TB hospitalization 
expenditures in the United States.
CONCLUSION
Using in-patient claims data for privately insured patients over a 5-year period (2010–2014), 
we estimated that the average hospitalization expenditure for in-patient stays with a principal 
TB diagnosis was US$33 085 in 2014. However, the average medical expenditures were 
significantly higher for some forms of EPTB than for PTB. In fact, although there were very 
few CNS TB disease patients compared to PTB patients, the estimated average expenditures 
for CNS TB were more than double those for PTB. When we extrapolated the results from 
our data to the entire US employer-based privately insured population, the overall total 
expenditures for TB hospitalization were US$154 million over the 5-year period (2010–
2014). Given that a substantial proportion of the direct costs of anti-tuberculosis treatment 
comes from hospitalization,3,5 and the introduction of the Affordable Care Act is expected to 
increase the provision of TB health care services in the private sector,6 our estimates provide 
timely benchmarks. Additional studies are needed to provide TB hospitalization estimates 
for patients insured by public providers (Medicare, Medicaid, Veterans Health 
Administration, etc.) and for uninsured TB patients to be representative of the entire US 
population.
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Table 1
Patient and claim characteristics for in-patient admission records with a TB diagnosis code as the principal 
diagnosis (n = 825)
Variable Frequency n (%)
Age group, years
 <15 56 (7)
 15–44 390 (47)
 ≥45 379 (46)
Number of admissions
 1 769 (93)
 >1 56 (7)
Admission type
 Surgical 241 (29)
 Medical 584 (71)
Discharge status
 Alive (discharged/transferred/left) 809 (98)
 Died 16 (2)
Sex
 Male 458 (56)
 Female 367 (44)
Region*
 South 324 (39)
 Northeast 171 (21)
 North Central 123 (15)
 West 192 (23)
 Unknown 15 (2)
TB disease site categories (ICD-9 codes)
 Pulmonary (011.0–011.96) 593 (72)
 Other respiratory (012.0–012.86) 35 (4)
 Central nervous system (013.0–013.96) 49 (6)
 Intestinal (014.0–014.86) 31 (4)
 Bone and joint (015.0–015.96) 42 (5)
 Genitourinary and not elsewhere classified (016.0–017.96) 31 (4)
 Miliary/disseminated (018.0–018.96) 44 (5)
Year
 2010 179 (22)
 2011 181 (22)
 2012 179 (22)
 2013 139 (17)
 2014 147 (18)
Drug benefit
 No 203 (25)
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Variable Frequency n (%)
 Yes 622 (75)
Type of health plan
 Comprehensive 10 (1)
 Exclusive Provider Organization 3 (4)
 Health Maintenance Organization 103 (13)
 POS 49 (6)
 Preferred Provider Organization 530 (67)
 POS with capitation 4 (0)
 Consumer Driven Health Plan 37 (5)
 High Deductible Health Plan 23 (3)
Age, years, mean ± SD; median (range) 40 ± 17; 43 (1–64)
Length of stay, days, mean ± SD; median (range) 10 ± 12; 8 (1–121)
*South: Delaware, Maryland, District of Columbia, West Virginia, Virginia, Kentucky, North and South Carolina, Georgia, Tennessee, Florida, 
Alabama, Mississippi, Arkansas, Louisiana, Oklahoma and Texas; Northeast: Maine, New Hampshire, Massachusetts, Vermont, Rhode Island, 
Connecticut, New York, New Jersey and Pennsylvania; North Central: Ohio, Michigan, Indiana, Illinois, Wisconsin, Minnesota, Iowa, Missouri, 
Kansas, Nebraska, South and North Dakota; West: Washington, Oregon, Montana, Idaho, Wyoming, Colorado, Utah, Nevada, California, Arizona, 
New Mexico, Hawaii and Alaska.13
TB =tuberculosis; ICD =International Classification of Disease; POS =point of service; SD = standard deviation.
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Table 2
Regression analyses used to determine the adjusted medical expenditures for TB hospitalization*
Variable β (95%CI)† Transformed coefficient in % (95%CI)‡
Length of stay, days 0.0367 (0.0301 to 0.0433) 3.7 (3.0 to 4.3)
Age group, years
 <15 Reference
 15–44 0.0640 (−0.1281 to 0.2561)
 ≥45 0.2020 (0.0082 to 0.3957) 22 (1 to 49)
Number of admissions
 1 Reference
 >1 0.3041 (0.0975 to 0.5107) 36 (10 to 67)
Admission type
 Surgical Reference
 Medical −0.5178 (−0.6239 to −0.4116) −40 (−46 to −34)
Discharge status
 Alive (discharged/transferred) Reference
 Died 0.2950 (−0.0948 to 0.6848)
Sex
 Male Reference
 Female 0.0276 (−0.0784 to 0.1336)
Region§
 South Reference
 Northeast 0.2289 (0.1064 to 0.3514) 26 (11 to 42)
 North Central 0.0560 (−0.0881 to 0.2000)
 West 0.6486 (0.5275 to 0.7697) 91 (69 to 116)
 Unknown 0.1452 (−0.1800 to 0.4705)
Site of TB disease
 Pulmonary Reference
 Other respiratory 0.0913 (−0.0658 to 0.2484)
 Central nervous system 0.7228 (0.5340 to 0.9116)¶ 106 (71 to 149)
 Intestinal −0.1814 (−0.3998 to 0.0369)
 Bone and joint 0.4645 (0.1567 to 0.7724)¶ 59 (17 to 116)
 Genitourinary and not elsewhere classified −0.0617 (−0.3461 to 0.2227)
 Miliary/disseminated 0.2344 (0.0474 to 0.4215)# 26 (5 to 52)
Year
 2010 Reference
 2011 0.0560 (−0.0702 to 0.1823)
 2012 −0.0331 (−0.1565 to 0.0903)
 2013 0.0934 (−0.0316 to 0.2183)
 2014 0.0289 (−0.0824 to 0.1402)
Drug benefit
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Variable β (95%CI)† Transformed coefficient in % (95%CI)‡
 No Reference
 Yes 0.0736 (−0.0501 to 0.1972)
Type of health plan
 Preferred Provider Organization Reference
 Comprehensive 0.0959 (−0.5740 to 0.7657)
 Exclusive Provider Organization −0.1036 (−0.3124 to 0.1052)
 Health Maintenance Organization 0.1036 (−0.0304 to 0.2377)
 POS 0.2081 (0.0084 to 0.4079)# 23 (1 to 50)
 POS with capitation −0.0238 (−0.7895 to 0.7419)
 Consumer Driven Health Plan 0.0295 (−0.1851 to 0.2442)
 High Deductible Health Plan 0.0342 (−0.1855 to 0.2538)
*
Dependent variable was the total payment for each patient.
†
Derived from bootstrap-generated standard errors with 50 replications.
‡Only coefficients with significant P values (<0.05) were transformed for easier interpretation of main effects. Because of the log-link specification, 
the coefficients were transformed as coefficient (β)*100 and interpreted as the relative change (in percentage) per unit change in the independent 
variable for continuous independent variables, and as (eβ − 1)*100 and interpreted as the relative increase or decrease (in percentage) in the 
estimated medical expenditures when compared with the reference (or omitted) category.22
§See Table 1 for geographical distribution.
¶P < 0.01.
#P < 0.05.
TB = tuberculosis; CI = confidence interval; ICD = International Classification of Disease; POS = point of service.
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Table 3
Estimated average medical expenditures of TB hospitalization by disease site category and overall from in-
patient claims data, 2010–2014
TB disease site categories (ICD-9)
Unadjusted expenditures*
Average ± standard deviation
Adjusted expenditures*
Average (95%CI)
Pulmonary (011.0–011.96) 37 253 ± 57 541 28 058 (26 632–29 484)
Other respiratory (012.0–012.86) 43 327 ± 29 744 35 436 (29 470–41 401)
Central nervous system (013.0–013.96) 110 743 ± 139 705 73 065 (59 572–86 558)†
Intestinal (014.0–014.86) 39 746 ± 62 304 27 852 (23 058–32 646)
Bone and joint (015.0–015.96) 80 685 ± 79 157 56 842 (39 301–74 383)†
Genitourinary and not elsewhere classified (016.0–017.96) 35 575 ± 41 557 22 419 (16 657–28 182)
Miliary/disseminated (018.0–018.96) 83 766 ± 106 893 55 487 (46 101–64 873)†
 All (011.0–018.96) 46 598 ± 71 497 33 085 (31 606–34 565)
*All expenditures are in 2014 US dollars.
†Significantly (P < 0.05) higher than the adjusted average expenditures for pulmonary TB disease.
TB = tuberculosis; CI = confidence interval; ICD = International Classification of Disease.
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